Abstract:Keywords: Glaucoma, Coenzyme Q10, Citicoline, Neuroprotection, Retinal ganglion cells. Glaucoma is a leading cause of irreversible blindness worldwide. Although the multifactorial genesis, by now, the main treatable risk factor is the elevated intraocular pressure. Nevertheless, some patients, whose intraocular pressure is considered at the target level, still experience a progression of the disease. New evidence strongly suggesting brain involvement in all aspects of the disease led to a growing interest in the pharmacological research of new neuroprotective agents with an intraocular pressure independent activity. Citicoline and coenzyme Q10 are among the most studied and used molecules in clinical practice for some forms of neurodegeneration. In particular, the neuromodulatory and neuroprotective properties of citicoline were extensively investigated either in vivo or in vitro studies. Among the activities of citicoline it has been proposed the capacity to increase neuronal viability as well as the vasomodulatory effect that results in an increased blood flow. Similarly, the neuroprotective effects of coenzyme Q10 has been proposed in experimental models of ocular neurodegeneration. The greater efficacy of the fixed combination over the single components could depend on the fact that each molecule exerts, at least in part, its activity on mitochondria. Coenzyme Q10 acts as an electron carrier from mitochondrial complexes I and II to III, while citicoline maintains proper levels of cardiolipin and sphingomyelin in the cellular and axon membranes. Thus, increasing the energetic rate of cells. Citicoline and coenzyme Q10 are reported to counteract excitotoxicity by respectively decreasing nitrosative stress and extracellular signal‐regulated kinases 1/2, and preventing the upregulation of NR1 and NR2A subunit receptors. In addition, coenzyme Q10 significantly prevents apoptosis by acting on Bax and pBad proteins expression and preserves mitochondrial DNA content and mitochondrial oxidative phosphorylation system in experimental models. Citicoline and coenzyme Q10 are also important in preventing retinal ganglion cells death possibly by acting on Bcl family regulation increasing retinal expression of Bcl‐2, and by significantly inducing Bcl‐xL protein expression, respectively. Citicoline and coenzyme Q10 also show an anti‐inflammatory effect; the first acting on inhibition of phospholipase A2 and downregulating synaptophysin, and the latter by downregulating tumour necrosis factor α and protein 1α, as well as acting on macrophage induced inflammation. Data on literature indicates that the combined use of molecules may be also beneficial for the metabolism of the molecules themselves. In fact, coenzyme Q10 increases the choline oxidase activity in ubiquinone‐depleted mitochondria, thus underling the importance of the presence of good plasmatic choline and coenzyme Q10 levels for energetic production. Overall, evidence seems to suggest the usefulness of coenzyme Q10 and citicoline, eventually combined, in the prevention of glaucomatous neurodegeneration.

The use of vitamin E in ocular health: Bridging omics approaches with Tocopherol and Tocotrienol in the management of glaucoma

Options for Topical Treatment of Oxidative Eye Diseases with a Special Focus on Retinopathies

Therapeutic Potential of Antioxidants and Hybrid TEMPOL Derivatives in Ocular Neurodegenerative Diseases: A Glimpse into The Future

Natural therapies for ocular disorders, part two: cataracts and glaucoma

Clinical management of eye diseases: carotenoids and their nanoformulations as choice of therapeutics

Omics approaches for assessing nutrition and ocular health in the modern era

The rise, the fall and the renaissance of vitamin E

Topical nutraceutical Optixcare EH ameliorates experimental ocular oxidative stress in rats

Advanced drug delivery and targeting technologies for the ocular diseases

Exploring New Therapeutic Avenues for Ophthalmic Disorders: Glaucoma-Related Molecular Docking Evaluation and Bibliometric Analysis for Improved Management of Ocular Diseases

Potential Properties of Natural Nutraceuticals and Antioxidants in Age-Related Eye Disorders

NAD+ and Niacin Supplementation as Possible Treatments for Glaucoma and Age-Related Macular Degeneration: A Narrative Review

Antioxidant nanoemulsion loaded with latanoprost enables highly effective glaucoma treatment

Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems

Treatment of Glaucoma with Natural Products and Their Mechanism of Action: An Update

Oculomics: A Crusade Against the Four Horsemen of Chronic Disease

Application of Convergent Science and Technology toward Ocular Disease Treatment

Resveratrol and Ophthalmic Diseases

Combined use of neuroprotective agents: A new treatment strategy for patients with glaucoma

Insights into ocular therapeutics: A comprehensive review of anatomy, barriers, diseases and nanoscale formulations for targeted drug delivery

Review article vitamin E: a multi-functional ingredient for health enhancement and food preservation